Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1902 | Immunoglobulin Wiki | 0.71 |
| drug3850 | Synthetic neutralising antibodies Wiki | 0.71 |
| drug1081 | Corticosteroid Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D018352 | Coronavirus Infections NIH | 0.05 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.03 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
Interferon lambda is one of the main arms of the innate antiviral immune response and is critical for controlling respiratory viral infections in mice. Interferon lambda has a better side effect profile than other interferons because of the limited tissue distribution of its receptor. Peginterferon lambda is a long-acting form that has been studied extensively in human trials in viral hepatitis, confirming its safety. We propose to evaluate peginterferon-lambda in ambulatory and hospitalized patients with mild to moderate COVID-19.
Description: The proportion of participants with negative SARS-CoV-2 RNA on nasopharyngeal swab.
Measure: Cohort A (Ambulatory) - Proportion swab negative at day 7 (Primary efficacy endpoint) Time: At day 7Description: The rate of treatment-emergent and treatment-related serious adverse events (SAEs)
Measure: Cohort A (Ambulatory) - Treatment-emergent and treatment related serious adverse events (Primary Safety Endpoint) Time: Day 0 to Day 30Description: Time to SARS-CoV-2 RNA negativity.
Measure: Cohort B (Hospitalized) - Time to viral negativity (Primary Efficacy Endpoint) Time: Day 0 to day 28Description: The rate of treatment-emergent and treatment-related serious adverse events (SAEs)
Measure: Cohort B (Hospitalized) - treatment-emergent and treatment-related serious adverse events (Primary Safety Endpoint) Time: Day 0 to Day 30Description: Time to resolution of symptoms (fever, cough, diarrhea)
Measure: Cohort A (Ambulatory) - Symptom Resolution (Clinical Outcome #1) Time: Day 0 to Day 14Description: Change in relative categorical symptom scores (respiratory, gastrointestinal, fever) - none, mild, moderate, severe and no change, worse, better
Measure: Cohort A (Ambulatory) - Symptom severity scores (Clinical Outcome #2) Time: Day 0 to Day 7Description: Proportion with need for hospital admission
Measure: Cohort A (Ambulatory) - Hospitalization (Clinical Outcome #3) Time: Day 0 to Day 14Description: Adverse events and serious adverse events
Measure: Cohort A (Ambulatory) - Adverse and serious adverse events (Clinical Outcome #4) Time: Day 0 to Day 14Description: Proportion negative for SARS-CoV-2 RNA by nasopharyngeal swab
Measure: Cohort A (Ambulatory) - Swab negative at day 3 (Virologic/Immunological Outcome #1) Time: At Day 3Description: Time to SARS-CoV-2 RNA negativity on mid-turbinate nasal swab or saliva
Measure: Cohort A (Ambulatory) - Time RNA negativity (Virologic/Immunological Outcome #2) Time: Day 0 to Day 14Description: Proportion with SARS-CoV-2 RNA in blood.
Measure: Cohort A (Ambulatory) - Proportion viremic (Virologic/Immunological Outcome #3) Time: Day 0 and Day 7Description: Proportion with SARS-CoV-2 antibodies blood
Measure: Cohort A (Ambulatory) - Proportion with antibodies (Virologic/Immunological Outcome #4) Time: Day 0 and Day 7Description: Correlation of virologic response with interferon lambda 4 (IFNL4) genotype
Measure: Cohort A (Ambulatory) - Correlation with interferon lambda 4 genotype (Virologic/Immunological Outcome #5) Time: Through day 7Description: Proportion with symptom development in household contacts (categorical symptom type yes/no)
Measure: Cohort A (Ambulatory) - Symptoms in household contacts (Transmission Outcome #1) Time: Day 0 to Day 14Description: Proportion with confirmed diagnosis of COVID-19 in household contacts
Measure: Cohort A (Ambulatory) - COVID-19 in household contacts (Transmission Outcome #2) Time: At Day 30Description: Proportion with ICU admission during hospitalization
Measure: Cohort B (Hospitalized) - ICU admission (Clinical Outcome #1) Time: Day 0 to day 30Description: Proportion with need for intubation
Measure: Cohort B (Hospitalized) - Need for intubation (Clinical Outcome #2) Time: Day 0 to Day 14Description: Length of hospital stay (days)
Measure: Cohort B (Hospitalized) - Length of hospital stay (Clinical Outcome #3) Time: Day 0 to Day 14Description: Change in respiratory symptom score (score 0 to 7 with higher scores indicating more severe disease)
Measure: Cohort B (Hospitalized) - Change in respiratory symptom score (Clinical Outcome #4) Time: Day 0 to 7 and Day 0 to 14Description: Proportion with readmission to hospital
Measure: Cohort B (Hospitalized) - Readmission to hospital (Clinical Outcome #5) Time: By day 30 and Day 90Description: All-cause mortality
Measure: Cohort B (Hospitalized) - All-cause mortality (Clinical Outcome #6) Time: At day 30 and day 90Description: COVID-19-related mortality
Measure: Cohort B (Hospitalized) - COVID-19-related mortality (Clinical Outcome #7) Time: At day 30Description: Adverse (AEs) and Serious Adverse Events (SAEs)
Measure: Cohort B (Hospitalized) - Adverse (AEs) and Serious Adverse Events (SAEs) (Clinical Outcome #8) Time: Day 0 to day 30Description: Frequency of dose reduction or dose omission for the second dose of peginterferon lambda
Measure: Cohort B (Hospitalized) - Dose reduction or dose omission (Clinical Outcome #9) Time: Day 7 to day 11Description: Proportion negative for SARS-CoV-2 RNA by nasopharyngeal swab.
Measure: Cohort B (Hospitalized) - Proportion negative swab. (Virologic/Immunological Outcome #1) Time: Day 7Description: Proportion negative for SARS-CoV-2 by nasopharyngeal swab
Measure: Cohort B (Hospitalized) - Proportion negative by day 14 (Virologic/Immunological Outcome) #2) Time: Day 14Description: Time to SARS-CoV-2 RNA negativity by rectal swab
Measure: Cohort B (Hospitalized) - Time to negativity by rectal swab (Virologic/Immunological Outcome #3) Time: Day 0 to day 14Description: Correlation of virologic response with interferon lambda 4 (IFNL4) genotype
Measure: Cohort B (Hospitalized) - Correlation with interferon lambda 4 (IFNL4) genotype (Virologic/Immunological Outcome #4) Time: Through Day 14Description: Proportion with SARS-CoV-2 Antibody.
Measure: Cohort B (Hospitalized) - Proportion with Antibody (Virologic/Immunological Outcome #6) Time: At Day 7 and Day 14Description: Proportion with SARS-CoV-2 RNA in blood
Measure: Cohort B (Hospitalized) - Proportion with viremia (Virologic/Immunological Outcome #7) Time: Day 0, Day 7, and Day 14The main purpose of this research study is to test the safety and effectiveness of an investigational drug peginterferon lambda-1a in treating COVID-19.
Description: The clinical improvement as defined as resolution of hypoxia requiring supplemental oxygen to maintain SpO2>92% at 7 days.
Measure: Number of participants with resolution of hypoxia Time: 7 daysDescription: Number of Grade 3 or 4 adverse events as determined by the DAIDS criteria over the course of 3 months from initiation of trial to measure safety and tolerability of pegylated interferon lambda. Information on adverse events will be collected during hospitalization and then as an outpatient until 90 days from the time of receipt of treatment.
Measure: Number of adverse events. Time: until 90 days after receipt of treatmentDescription: Number of days participant has a fever. Information on fever will be collected during hospitalization. Cessation of fever is defined as the beginning of the first 48 hour period without fever without the use of antipyretic drug.
Measure: Days with fever Time: during hospitalization, average of 7 daysDescription: This is defined as time from initial treatment with investigational agent, to the cessation of fever, defined as the beginning of the first 48 hour period without fever without the use of antipyretic drug.
Measure: Time to resolution of fever Time: during hospitalization, average of 7 daysDescription: Defined as time from initial treatment with investigational agent to deterioration of clinical condition necessitating transfer to a critical care unit and/or intubation.
Measure: Rate of progression to requiring critical care Time: during hospitalization, average of 5 daysDescription: Information on survival will be collected during hospitalization and then, for those patients discharged, will be collected as an outpatient until 90 days from the time of receipt of treatment
Measure: Overall survival Time: until 90 days after receipt of treatmentDescription: This is defined as the amount of time (in days or fraction thereof) between the receipt of investigational agent and discharge from The Mount Sinai Hospital to home or nursing home, or censoring at time of death.
Measure: Time to discharge Time: average of 7 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports